Citations

Clear

5486 citation(s) found for "Yu, Stephen".

METB-05. NON-INVASIVE DIAGNOSIS OF BRAINSTEM GLIOMAS IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS THROUGH CEREBROSPINAL FLUID CELL-FREE DNA SEQUENCING
Hill, Katherine , Holle, Bridget, Bouvier, Nancy , Li, Shanita , Stockfisch, Emily , Huereca, Claudia, DiNapoli, Sara , Hertz, Charli Ann J., Szalontay, Luca , Li, Bryan Kincheon, Riviere-Cazaux, Cécile , Haque, Sofia , Doğan, Snjezana , Borsu, Laetitia , Ross, Dara S. , Zampieri, Caroline Barbosa, Donzelli, Maria, Kramer, Kim , Gilheeney, Stephen W., Souweidane, Mark, Greenfield, Jeffery P, Arcila, Maria E. , Ladanyi, Marc , Miller, Alexandra , Vanderbilt, Chad , Giantini-Larsen, Alexandra , Hickman, Richard A. , Holle, Bridget M, Alano, Tina , Doe-Tetteh, Seyram A. , Lee, Alex , Burns, Terry C. , Bale, Tejus , Benhamida, Jamal K. , Chang, Jason C. , Zampieri, Caroline Chaul de Lima Barbosa, Dunkel, Ira J. , Sait, Sameer Farouk , Khakoo, Yasmin , Berger, Michael , Mellinghoff, Ingo K. , Karajannis, Matthias A.

Mayo Clinic

Neuro-Oncology | June 12, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: i31-i31

10.1093/neuonc/noad073.122 Get It

Abstract Intrinsic brainstem tumors arising in pediatric, adolescent, and young adult patients comprise a spectrum of entities, predominantly diffuse midline gliomas (DMG) and IDH mutant astrocytomas. Accurate molecular diagnosis is essential for prognostication and optimal therapy. Therapeutic considerations include inclusion (in IDH mutant) or exclusion (in H3K27M) of adjuvant Temozolomide post radiotherapy and use of molecular targeted therapy (IDH inhibitors). Surgical biopsy, however, is associated with increased risk of permanent neurological deficits and may yield insufficient or non-diagnostic tissue. We hypothesized that minimally-invasive “liquid biopsy” of cerebrospinal fluid (CSF) could represent a superior diagnostic modality in this patient population, employing molecular analysis of cell free DNA (cfDNA). We analyzed 44 CSF samples from 38 unique patients for recurrent driver mutations in brainstem gliomas, including H3K27M, IDH1, and IDH2. MSK-IMPACT, a NY state-authorized hybridization capture-based next-generation panel DNA sequencing assay, was used for analysis. Samples without a detectable driver mutation by MSK-IMPACT testing were further subjected to gene targeted testing by droplet digital PCR. In all, 10/44 (22.7%) samples had mutations detected by MSK-IMPACT using standard calling criteria and 13 of the remaining 34 samples (38.2%) had supporting evidence of a mutation based on manual review. Further testing by ddPCR was performed on a subset of cases (based on DNA availability) which confirmed 7 of the previous low-level mutations and uncovered 4 additional mutations. Overall, 27/44 (61.4%) of cases had detectable evidence of a mutation, and of the 23 patients without a known tissue diagnosis, a driver in the CSF was identified for 47.8% of patients (11/23). Minimally-invasive analysis of CSF cfDNA in patients with intrinsic brainstem tumors has a high diagnostic yield and may obviate the need for tissue biopsy in a majority of patients. Testing with high sensitivity assays is valuable to maximize the rate of detection.
Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia
Zanwar, Saurabh , Abeykoon, Jithma P. , Ansell, Stephen M. , Gertz, Morie A. , Mauermann, Michelle L. , Witzig, Thomas E. , Johnston, Patrick, Kyle, Robert A. , King, Rebecca L. , Kumar, Shaji , Kapoor, Prashant , Witzig, T.E. , Kumar, Shaji K , Kapoor, Prashant , Gertz, Morie A , Mauermann, Michelle L , Habermann, Thomas M.

Mayo Clinic

Leukemia & Lymphoma | June 10, 2023 | Volume: 64 | Issue: 8 | Pages: 1490-1493

10.1080/10428194.2023.2214026 | PMID 37300306 Get It

Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY
Pinto, A. A., Bisneto, J. C. Villasboas, Sanz, R. García, García, Carlos Grande, Smith, Stephen D. , Wallace, D. S., Merryman, R., Marolleau, Jean Pierre, Chêne, Laurent , Fagerberg, Jan, Friedberg, Jonathan W. , Ansel, Sonam , Armand, Philippe , Pinto, A., Bosch, Francesc , Bisneto, J. C. Villasboas, Sanz, R. García, Arcaini, Luca , Marolleau, Jean‐Pierre, Filippi, Rosaria De , Bonny, Christophe , Ansel, S., Zinzani, Pier Luigi

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 581-582

10.1002/hon.3164_435 Get It

Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL)
Shreve, Jacob , Bock, Allison M. , Shah, M. V., Wang, Y., Nowakowski, Grzegorz S. , Novak, Anne J. , Young, Jason R., Ansell, Stephen M. , Hazim, Antonious , Pritchett, Joshua C. , Maurer, Matthew J. , Binder, Moritz , Witzig, Thomas E. , Cerhan, James R. , Habermann, Thomas M. , Paludo, Jonas

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 341-342

10.1002/hon.3164_244 Get It

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 004
Maloney, David G. , Brander, Danielle M. , Dorritie, Kathleen , Shah, Nirav N. , Nath, R., Feldman, Tatyana , Solomon, Scott R. , Perna, Serena , Tuazon, Sherilyn A. , Ou, San San, Wierda, William G. , Siddiqi, Tanya , Kenderian, Saad S. , Soumerai, Jacob D. , Riedell, Peter A. , Fakhri, Bita , Stephens, Deborah M. , Ma, Shuo , Schuster, Stephen J. , Ou, San‐San , Papp, Eniko , Chen, Yuling , Wierda, William G.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 60-62

10.1002/hon.3163_26 Get It

Health‐related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso‐cel in TRANSCEND CLL 004
Maloney, David G. , Shah, Nirav N. , Eliason, Laurie , Wang, L., Tuazon, Sherilyn A. , Ou, San‐San , Siddiqi, Tanya , Fakhri, Bita , Ma, Shuo , Riedell, Peter A. , Schuster, Stephen J. , Shi, Lizheng , Ye, Xin , Kenderian, Saad S.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 538-541

10.1002/hon.3164_400 Get It

Characterization of the tumor microenvironment in classic Hodgkin lymphoma: determining the deep immunophenotypic signature of T cells using mass cytometry
Niu, Airu, Whitaker, Kristen , Yang, Zhizhang, Kim, Hyo Jin , Novak, Anne J. , Ansell, Stephen M. , Niu, A., Whitaker, K., Soekojo, Cinnie Yentia , Villasboas, José C.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 266-267

10.1002/hon.3164_179 Get It

SINGLE CELL ANALYSIS REVEALS IMMUNE DYSFUNCTION IN LARGE B CELL LYMPHOMA (LBCL) PTS WITH HYPOMAGNESEMIA RECEIVING AXI‐CEL: RESULTS FROM ZUMA‐1 TRIAL AND MAYO CLINIC COHORT
Bansal, Radhika , Gandhi, Sanyam, Babadi, Elham , McCoy, G., Shao, Zuoyi , Regan, Kate , Hathcock, Matthew , Ansell, Stephen M. , Johnston, Patrick B. , Khurana, Arushi , Moreno, Elia Martínez , Kharfan‐Dabaja, Mohamed A. , Mattie, M., Bot, Adrian , Rossi, J. , Mondello, Patrizia , Gile, Jennifer , Wang, Ziyi , Li, Y., Gandhi, S., Zhang, H., Martinez, K., McCoy, G., Regan, K., Bennani, N. Nora , Paludo, Jonas , Villasboas, José C. , Wang, Peng , Durani, Urshila , Moreno, E., Castro, Januario E. , Murthy, Hemant S. , Kenderian, Saad S. , Rossi, J., Witzig, Thomas E. , Lin, Yi

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 228-230

10.1002/hon.3163_150 Get It